A cancer drug which can flush out dormant HIV

University of North Carolina at Chapel Hill in a study found the existence of persistent reservoirs of dormant HIV in the immune system that are not attacked by anti-AIDS drugs, believed to be a major reason why infection re-emerges once patients stop taking their medication.

The disruption and clearance of these reservoirs is critical to finding a cure for AIDS.

Researchers at UNC, working in collaboration with scientists from the Harvard School of Public Health, National Cancer Institute and the University of California undertook a series of experiments designed to evaluate the potential of the drug vorinostat.

Vorinosta is a deacetylase inhibitor that is used to treat some types of lymphoma, to activate and disrupt the dormant virus.

Laboratory experiments measuring active HIV levels in CD4+ T cells, which are specialized white blood cells that the virus uses to replicate, showed that vorinostat unmasked the hidden virus in these cells.

Subsequently, vorinostat was administered to eight HIV-infected men who were medically stable on antiretroviral therapy and the levels of active HIV virus were measured and compared to the levels prior to administration.

Patients receiving vorinostat showed an average 4.5-fold increase in the levels of HIV RNA in CD4+ T cells, evidence that the virus was being unmasked.

"This work provides compelling evidence for a new strategy to directly attack and eradicate latent HIV infection," said David Margolis, MD, professor at the University of North Carolina at Chapel Hill.

The study is published in scientific journal 'Nature'.

Targeting latency is the first step on a path that may lead to a cure.

"Long-term, widespread use of antiretrovirals has personal and public health consequences, including side effects, financial costs, and community resistance. We must seek other ways to end the epidemic, and this research provides new hope for a strategy to eradicate HIV completely from the body," said Margolis, who led the study.

  

University of North Carolina at Chapel Hill in a study found the existence of persistent reservoirs of dormant HIV in the immune system that are not attacked by anti-AIDS drugs, believed to be a major reason why infection re-emerges once patients stop taking their medication.

The disruption and clearance of these reservoirs is critical to finding a cure for AIDS.

Researchers at UNC, working in collaboration with scientists from the Harvard School of Public Health, National Cancer Institute and the University of California undertook a series of experiments designed to evaluate the potential of the drug vorinostat.

Vorinosta is a deacetylase inhibitor that is used to treat some types of lymphoma, to activate and disrupt the dormant virus.

Laboratory experiments measuring active HIV levels in CD4+ T cells, which are specialized white blood cells that the virus uses to replicate, showed that vorinostat unmasked the hidden virus in these cells.

Subsequently, vorinostat was administered to eight HIV-infected men who were medically stable on antiretroviral therapy and the levels of active HIV virus were measured and compared to the levels prior to administration.

Patients receiving vorinostat showed an average 4.5-fold increase in the levels of HIV RNA in CD4+ T cells, evidence that the virus was being unmasked.

"This work provides compelling evidence for a new strategy to directly attack and eradicate latent HIV infection," said David Margolis, MD, professor at the University of North Carolina at Chapel Hill.

The study is published in scientific journal 'Nature'.

Targeting latency is the first step on a path that may lead to a cure.

"Long-term, widespread use of antiretrovirals has personal and public health consequences, including side effects, financial costs, and community resistance. We must seek other ways to end the epidemic, and this research provides new hope for a strategy to eradicate HIV completely from the body," said Margolis, who led the study.